Development of the first targeted therapy for translocation RCC

Ended Project Grant Awarded Last action

Award ID
W81XWH2210901
Recipient
Awarding agency
Obligated
$130,698

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $130,698 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support the development of the first targeted therapy for translocation renal cell carcinoma from August 15, 2022 to August 14, 2023. As the parent organization of the awardee, Partners Healthcare System Incorporated will oversee delivery of this innovative medical research effort to develop new treatment options for this form of kidney cancer commonly affecting military service members and the general public. The Military Medical Research and Development program aims to transform healthcare through impactful biomedical research addressing medical challenges on the battlefield and beyond.

Quick answers

Who received award W81XWH2210901?

W81XWH2210901 was awarded to Brigham & Womens Hospital Inc. by Medical Command (Department of the Army) on August 15, 2022.

How much is award W81XWH2210901 worth?

$130,698 has been obligated on W81XWH2210901.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login